

Anatara Market Update – COVID-19

MELBOURNE, 7th April 2020: Anatara Lifesciences Ltd (ASX:ANR) provides an update on the impact to the Company of the COVID-19 pandemic.

The Company remains committed to its corporate strategy and focused on delivering on its anticipated milestones during the year ahead. However, the Company is actively planning for disruptions that may lead to delays in meeting some of these objectives.

Understandably, COVID-19 has caused delays in clinical research and manufacturing activities globally. The Australian Department of Health has provided COVID-19 guidance for clinical trials.

“The focus should remain on the safety and well-being of those most at risk in our institutions and communities.” “Any new recruitment should reflect the most current public health advice on social distancing.” “Researchers and sponsors should educate themselves about novel approaches to the conduct of clinical trials, such as decentralised trials (i.e. teletrials) and hybrid models in which participants can be recruited and participate remotely and data can be captured remotely via available technology.”¹

Given the disruptions, Anatara is reviewing possible paths forward and gathering information on realistic trial delivery so that we may be able to commence our upcoming human clinical trial as soon as practicable. Anatara will proceed with a planned decentralised trial design, allowing participants to be recruited and participate remotely. It is anticipated that this trial design will enable recruitment of participants and higher retention rates than traditional centralised trials. At the current time, Anatara anticipates a delay, to the second half of 2020, for the commencement of its clinical trial in irritable bowel syndrome (IBS) for its Gastrointestinal ReProgramming (GaRP) over-the-counter medicine.

We continue to advance our licensing discussions with potential animal health partners for our core animal asset, Detach[®], with the aim of meeting our partnering milestone of end Q2 2020. We do not anticipate a material delay due to the COVID-19 pandemic. Anatara will monitor developments around COVID-19 and if needed, will update the market accordingly.

As at 31 March 2020, Anatara held cash and equivalents of 3.3 million. No commitments have been made for future in-licensing opportunities at this time and as a precautionary measure, the Company has put in place measures to reduce all non-critical expenditure. The anticipated delay in commencement of the GaRP clinical trial extends Anatara’s cash runway. The Company will review funding needs in the second half of the year.

Furthermore, in line with current federal and state COVID-19 guidelines, the Company has implemented a number of measures to protect the wellbeing of staff:



- Employee training on infectious disease awareness and working-from-home-effectively
- Suspension of all corporate travel until further notice
- Encouraging staff to work from home where appropriate
- Non-attendance at investor events, industry conferences and trade shows (except where virtual participation is provided) until further notice

Anatara CEO, Mr Steven Lydeamore said, “During these uncertain times, the Company remains optimistic that the impact of the COVID-19 pandemic will be limited to medium-term delays in accomplishing our corporate objectives. We continue to work remotely on our upcoming GaRP clinical trial activities and maintain ongoing discussions with potential animal health and human consumer health partners.”

“The Company remains highly encouraged by the successful preclinical data reported for GaRP to date, providing the Company with every confidence going into a human clinical study later this year.”

¹ Australian Government Department of Health, COVID-19: Guidance on clinical trials for institutions, HRECs, researchers and sponsors, <https://www1.health.gov.au/internet/main/publishing.nsf/Content/Clinical-Trials>

For more information please contact:

Investor inquiries	Media inquiries
Steven Lydeamore CEO, Anatara Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anatara.com	Sue MacLeman Chair, Anatara Lifesciences Ltd +61 (0) 437 211 200 smacleman@anatara.com

About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.